Does TOCILIZUMAB Cause Bladder transitional cell carcinoma? 68 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 68 reports of Bladder transitional cell carcinoma have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 0.1% of all adverse event reports for TOCILIZUMAB.
68
Reports of Bladder transitional cell carcinoma with TOCILIZUMAB
0.1%
of all TOCILIZUMAB reports
0
Deaths
62
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From TOCILIZUMAB?
Of the 68 reports, 62 (91.2%) required hospitalization.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 68 reports have been filed with the FAERS database.
What Other Side Effects Does TOCILIZUMAB Cause?
Drug ineffective (32,342)
Rheumatoid arthritis (20,652)
Pain (18,384)
Off label use (18,256)
Arthralgia (15,536)
Joint swelling (14,831)
Fatigue (13,802)
Rash (12,327)
Drug intolerance (11,952)
Contraindicated product administered (11,547)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
RANITIDINE (41)
Which TOCILIZUMAB Alternatives Have Lower Bladder transitional cell carcinoma Risk?
TOCILIZUMAB vs TOCILIZUMAB-AAZG
TOCILIZUMAB vs TOCOPHEROL
TOCILIZUMAB vs TOFACITINIB
TOCILIZUMAB vs TOFERSEN
TOCILIZUMAB vs TOLNAFTATE